Mode
Text Size
Log in / Sign up
N/A N=374 Randomized Double-blind Treatment

Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial

Pelvic Organ Prolapse (POP)

Enrolled (actual)
374
Serious AEs
16.6%
Results posted
Oct 2020
Primary outcome: Primary: Surgical Success — 25; 30; 28; 27 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SSLF (Procedure); ULS (Procedure); PMT (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
NICHD Pelvic Floor Disorders Network
Primary completion
Jul 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Surgical Success
25; 30; 28; 27; 47; 47
PRIMARY
Anatomic Failure
18; 23; 19; 19; 58; 56
PRIMARY
Urinary Distress Inventory at 6 Months
30.6; 37.9; 27.4; 29.7
SECONDARY
Change From Baseline: Urinary Distress Inventory
-88.1; -84.9; -82.5; -82.9
SECONDARY
Change From Baseline: Pelvic Organ Prolapse Distress Inventory
-77.4; -70.6; -79.3; -66.4
SECONDARY
Change From Baseline: Colorectal Anal Distress Inventory
-48.6; -46.5; -61.4; -52.4
SECONDARY
Urinary Impact Questionnaire Change From Baseline to 24 Months
-84; -72.6; -79; -97.6
SECONDARY
Pelvic Organ Prolapse Impact Questionnaire Change From Baseline to 24 Months
-67.5; -49.1; -59.4; -82.2
SECONDARY
Colorectal-Anal Impact Questionnaire Change From Baseline to 24 Months
-40.9; -21.6; -29.2; -42.5
SECONDARY
Sexual Function 36 - Physical Health Component Score Change From Baseline to 24 Months
7.9; 4.8; 4.8; 6
SECONDARY
Sexual Function 36 - Mental Health Component Score Change From Baseline to 24 Months
0.6; 2; 2.5; 1.1
SECONDARY
Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire Change From Baseline to 24 Months
5.6; 4.6; 3.8; 6.6

Summary

Pelvic organ prolapse is common among women with a prevalence that has been estimated to be as high as 30%. Pelvic organ prolapse often involves a combination of support defects involving the anterior, posterior and/or apical vaginal segments. While the anterior vaginal wall is the segment most likely to demonstrate recurrent prolapse after reconstructive surgery, reoperations are highest among those who require apical suspension procedures with or without repair of other vaginal segments (12%-33%). Despite the substantial health impact, there is a paucity of high quality evidence to support different practices in the management of prolapse, particularly surgery. Thus, the objectives of the Operations and Pelvic Muscle Training in the Management of Apical Support Loss (OPTIMAL) Trial are: 1. to compare sacrospinous ligament fixation (SSLF) to uterosacral vaginal vault ligament suspension (ULS); and 2. to assess the role of perioperative behavioral therapy/pelvic muscle training (PMT) in women undergoing vaginal surgery for apical or uterine prolapse and stress urinary incontinence.

Eligibility Criteria

Inclusion Criteria

  • Stage 2 to 4 prolapse
  • Prolapse of the vaginal apex or cervix to at least half way into the vaginal canal (POPQ Point C > -TVL/2) [TVL stands for total vaginal length]
  • Vaginal bulge symptoms as indicated by an affirmative response to either questions on the Pelvic Floor Distress Inventory (PFDI)
  • Vaginal surgery for prolapse is planned, including a vaginal apical suspension procedure.
  • Stress incontinence symptoms as indicated by an affirmative response to the PFDI Stress incontinence subscale
  • Documentation of transurethral stress leakage on an office stress test or urodynamics with or without prolapse reduction within the previous 12 months
  • A tension free vaginal tape (TVT) is planned to treat stress urinary incontinence.
  • A pelvic muscle training (PMT) visit can be performed at least 2 weeks and not more than 4 weeks before surgery.
  • Available for 24-months of follow-up.
  • Able to complete study assessments, per clinician judgment
  • Able and willing to provide written informed consent

Exclusion Criteria

  • Contraindication to sacrospinous ligament fixation (SSLF), uterosacral vaginal vault ligament suspension (ULS), or TVT in the opinion of the treating surgeon.
  • History of previous surgery that included a SSLF or ULS. (Previous vaginal vault suspensions using other techniques or in which the previous technique is unknown are eligible.)
  • Pelvic pain or dyspareunia due to levator ani spasm that would preclude a PMT program.
  • History of previous synthetic sling procedure for stress incontinence.
  • Previous adverse reaction to synthetic mesh.
  • Urethral diverticulum, current or previous (i.e., repaired)
  • History of femoral to femoral bypass.
  • Current cytotoxic chemotherapy or current or history of pelvic radiation therapy.
  • History of two inpatient hospitalizations for medical comorbidities in the previous 12 months.
  • Subject wishes to retain her uterus. [Both ULS and SLS include removal of the uterus, if not previously removed]
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00597935). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search